Pirtobrutinib: A New Hope for patients with BT... - CLL Support
Pirtobrutinib: A New Hope for patients with BTK-inhibitor refractory lymphoproliferative disorders
You need to be a member of this community to see this post.
12 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
EHA 2022: Outcomes Following Treatment With a Covalent BTK and BCL2 Inhibitor
https://cllsociety.org/2022/08/eha-2022-outcomes-following-treatment-with-a-covalent-btk-and-bcl2-in
Ibrutinib Slow but steady foreward movement.
Slowly things move forwards…
New Marketing Authorisation Application Submitted to EMA for...
Good News! BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax
3rd April 2020 Blood
Key points to note:
BTK inhibitor therapy achieves durable disease...
A new kid on the block? Nemtabrutinib
Hi All,
There is a new targeted drug in Clinical Trials that may offer a new treatment option for...
New drug: MS-553 inhibitor for CLL/SLL who develop resistance to BTK inhibitors
MS-553 is a protein kinase C-beta (PKCß) inhibitor designed to be an alternative treatment option...
Related Posts
Is thyroid hormone replacement allowed to take when you are on a BTK inhibitor?
Novel Bruton’s Tyrosine Kinase (BTK) inhibitor, ONO-4059 enters UK CLL clinical trial 
Time-Limited Triplet Emerges as a Potential Standard in Relapsed/Refractory CLL
Latest results questions
CALQUENCE gets FDA approval for treating CLL
